EF
KROS icon

Empowered Funds’s Keros Therapeutics KROS Stock Holding History

Empowered Funds’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52M Sell
142,151
-3,366
-2% -$37.5K 0.01% 1317
2026
Q1 		$1.61M Buy
+145,517
New +$2.25M 0.01% 1214

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Empowered Funds's KROS Position: Q2 2026 in Review

Empowered Funds reduced its Keros Therapeutics (KROS) stake by 2.3% in Q2 2026, selling an estimated $37.5K and leaving 142,151 shares worth $1.52M. The position accounts for 0.01% of the portfolio, ranked #1317.

Empowered Funds first reported a position in KROS in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.61M in Q1 2026. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Empowered Funds held 142,151 shares of Keros Therapeutics worth $1.52M as of Q2 2026.
  • Empowered Funds sold 3,366 Keros Therapeutics shares in Q2 2026, an estimated $37.5K.
  • Keros Therapeutics made up 0.01% of Empowered Funds's portfolio in Q2 2026, its #1317 holding.
  • Empowered Funds first reported a position in Keros Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Empowered Funds's Keros Therapeutics position peaked at $1.61M in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.